Protein Summary
Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Together with its cognate ligand/functional ligand EFNB2 plays a central role in heart morphogenesis and angiogenesis through regulation of cell adhesion and cell migration. EPHB4-mediated forward signaling controls cellular repulsion and segregation form EFNB2-expressing cells. Plays also a role in postnatal blood vessel remodeling, morphogenesis and permeability and is thus important in the context of tumor angiogenesis. Ephrin receptors and their ligands, the ephrins, mediate numerous developmental processes, particularly in the nervous system. Based on their structures and sequence relationships, ephrins are divi ...more
- ENST00000358173
- ENSP00000350896
- ENSG00000196411
- ENST00000616502
- ENSP00000482702
- HTK
- MYK1
- TYRO11
- HTK
- MYK1
- HFASD
- CMAVM2
- LMPHM7
- TYRO11
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
protein domain | 1 | ||
molecular function | 0.98 | ||
PubMedID | 0.86 | ||
transcription factor binding site profile | 0.83 | ||
kinase perturbation | 0.81 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 322.2 (req: < 5)
Gene RIFs: 134 (req: <= 3)
Antibodies: 627 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 322.2 (req: >= 5)
Gene RIFs: 134 (req: > 3)
Antibodies: 627 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 16
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 106
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 3